Acylated and desacyl ghrelin are associated with hepatic lipogenesis, β-oxidation and autophagy: role in NAFLD amelioration after sleeve gastrectomy in obese rats
Abstract:Bariatric surgery improves non-alcoholic fatty liver disease (NAFLD). Our aim was to investigate the potential role of ghrelin isoforms in the resolution of hepatic steatosis after sleeve gastrectomy, a restrictive bariatric surgery procedure, in diet-induced obese rats. Male Wistar rats (n = 161) were subjected to surgical (sham operation and sleeve gastrectomy) or dietary interventions [fed ad libitum a normal (ND) or a high-fat (HFD) diet or pair-fed]. Obese rats developed hepatosteatosis and showed decreas… Show more
“…For example, CR in acyl-ghrelin deficient (Goat -/-) mice leads to a reduction in LC3-II in liver, suggesting a decreased rate of autophagy (Yuanyuan Zhang, Fang, Goldstein, Brown, & Zhao, 2015). The treatment of hepatic cells with ghrelin leads to an increase in LC3-II, ATG5, ATG7 as well as a decrease in p62 (Sqstm1), consistent with increased rates of autophagy (Ezquerro et al, 2016). Ghrelin increases LC3 and Beclin1 in an AMPK dependent manner in rat smooth muscle cells (Xu, Liu, Song, Chen, & Gui, 2017), and ghrelin-induced autophagy may occur via activation of AMPK to prevent lipotoxicity in human liver cells (Mao et al, 2015).…”
Parkinson's disease is a common age-related neurodegenerative disorder affecting 10 million people worldwide, but the mechanisms underlying its pathogenesis are still unclear. The disease is characterised by dopamine nerve cell loss in the mid-brain and intra-cellular accumulation of α-synuclein that results in motor and non-motor dysfunction. In this review, we discuss the neuroprotective effects of the stomach hormone, ghrelin, in models of Parkinson's disease. Recent findings suggest that it may modulate mitochondrial function and autophagic clearance of impaired organelle in response to changes in cellular energy balance. We consider the putative cellular mechanisms underlying ghrelin-action and the possible role of ghrelin mimetics in slowing or preventing Parkinson's disease progression. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.'
“…For example, CR in acyl-ghrelin deficient (Goat -/-) mice leads to a reduction in LC3-II in liver, suggesting a decreased rate of autophagy (Yuanyuan Zhang, Fang, Goldstein, Brown, & Zhao, 2015). The treatment of hepatic cells with ghrelin leads to an increase in LC3-II, ATG5, ATG7 as well as a decrease in p62 (Sqstm1), consistent with increased rates of autophagy (Ezquerro et al, 2016). Ghrelin increases LC3 and Beclin1 in an AMPK dependent manner in rat smooth muscle cells (Xu, Liu, Song, Chen, & Gui, 2017), and ghrelin-induced autophagy may occur via activation of AMPK to prevent lipotoxicity in human liver cells (Mao et al, 2015).…”
Parkinson's disease is a common age-related neurodegenerative disorder affecting 10 million people worldwide, but the mechanisms underlying its pathogenesis are still unclear. The disease is characterised by dopamine nerve cell loss in the mid-brain and intra-cellular accumulation of α-synuclein that results in motor and non-motor dysfunction. In this review, we discuss the neuroprotective effects of the stomach hormone, ghrelin, in models of Parkinson's disease. Recent findings suggest that it may modulate mitochondrial function and autophagic clearance of impaired organelle in response to changes in cellular energy balance. We consider the putative cellular mechanisms underlying ghrelin-action and the possible role of ghrelin mimetics in slowing or preventing Parkinson's disease progression. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.'
“…Ghrelin activates AMPK in hepatocytes, promotes autophagy, stimulates mitochondrial biogenesis, and induces mitochondrial FFA b-oxidation, and thus ameliorates hepatic triglyceride overaccumulation (Ezquerro et al, 2016) (Figure 3A). In concert, ghrelin attenuates hepatic lipotoxicity by enhancing autophagy via restoration of the AMPK/mTOR signaling pathway (Mao et al, 2015a).…”
Section: The Role Of Ghrelin In Cellular Homeostasismentioning
Ghrelin, a gastric-derived acylated peptide, regulates energy homeostasis by transmitting information about peripheral nutritional status to the brain, and is essential for protecting organisms against famine. Ghrelin operates brain circuits to regulate homeostatic and hedonic feeding. Recent research advances have shed new light on ghrelin's multifaceted roles in cellular homeostasis, which could maintain the internal environment and overcome metaflammation in metabolic organs. Here, we highlight our current understanding of the regulatory mechanisms of the ghrelin system in energy metabolism and cellular homeostasis and its clinical trials. Future studies of ghrelin will further elucidate how the stomach regulates systemic homeostasis.
“…Furthermore, there is increasing evidence suggesting that autophagy plays a protective role in acute liver injury caused by a variety of challenges including LPS, cecal ligation and puncture (CLP), TNFα, APAP, ischemia/reperfusion, overload of fatty acids 18, 20–22 . It is possible that FK866 could protect liver injury through induction of autophagy.…”
FK866 exhibits a protective effect on D-galactosamine (GaIN)/lipopolysaccharide (LPS) and concanavalin A (ConA)-induced acute liver failure (ALF), but the mechanism by which FK866 affords this benefit has not yet been elucidated. Autophagy has a protective effect on acute liver injury. However, the contribution of autophagy to FK866-conferred hepatoprotection is still unclear. This study aimed to investigate whether FK866 could attenuate GaIN/LPS and ConA-induced ALF through c-jun-N-terminal kinase (JNK)-dependent autophagy. In vivo, Mice were pretreated with FK866 at 24, 12, and 0.5 h before treatment with GaIN/LPS and ConA. 3-methyladenine (3MA) or rapamycin were used to determine the role of autophagy in FK866-conferred hepatoprotection. In primary hepatocytes, autophagy was inhibited by 3MA or autophagy-related protein 7 (Atg7) small interfering RNA (siRNA). JNK was suppressed by SP600125 or Jnk siRNA. FK866 alleviated hepatotoxicity and increased autophagy while decreased JNK activation. Suppression of autophagy abolished the FK866-conferred protection. Inhibition of JNK increased autophagy and exhibited strongly protective effect. Collectively, FK866 could ameliorate GaIN/LPS and ConA-induced ALF through induction of autophagy while suppression of JNK. These findings suggest that FK866 acts as a simple and applicable preconditioning intervention to protect against ALF; autophagy and JNK may also provide therapeutic targets for ALF treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.